Global Vascular Co., Ltd.

[Vision and Mission] Global Vascular Co., Ltd., founded in December 2022 as a spin-off from Keio University, is a MedTech pioneer dedicated to addressing one of the most pressing challenges in modern vascular medicine: Peripheral Artery Disease (PAD). With more than 200 million people worldwide suffering from impaired mobility due to arterial blockages, the mission of Global Vascular is clear: "To ensure everyone can keep walking for life." By integrating cutting-edge academic research with industrial engineering, the company aims to deliver life-changing medical devices that prevent limb amputation and restore the freedom of movement.

[Breakthrough Innovation: BioStealth™ Technology] The cornerstone of the company’s innovation is the "BioStealth™ Technology." While endovascular treatment using stents has become common, small-caliber vessels—particularly those below the knee (BTK)—remain notoriously difficult to treat. Conventional stents often trigger immune responses leading to thrombus (blood clot) formation or restenosis (re-narrowing of the vessel). Global Vascular has overcome these barriers through a proprietary nanotechnology-driven coating and structural design. BioStealth™ allows the stent to remain "invisible" to the body’s immune system, facilitating rapid cell integration without inducing inflammation. This unique ability to harmonize a medical implant with human tissue represents a "stealth" approach that even global medical giants have yet to master. By focusing on the most challenging anatomical areas, Global Vascular is positioning itself at the absolute forefront of endovascular therapy.

[Business Growth and Global Outlook] The company has demonstrated remarkable traction since its inception. In January 2026, it was selected for the "Deep-Tech Startups Support Program" by NEDO (New Energy and Industrial Technology Development Organization), a testament to the strategic importance of its technology to Japan’s industrial future. Financially, the company successfully raised 1 billion yen in its Series B funding round in June 2025, supported by leading venture capitals and strategic partners such as Tokyo University of Science Innovation Capital and Medikit Co., Ltd. This robust financial backing is currently fueling the transition from research and development to clinical trials and regulatory approval processes. Headquartered in the vibrant innovation hub of Tokyo, Global Vascular is assembling a world-class team of engineers, researchers, and clinical experts. The company’s trajectory extends beyond PAD, with potential applications of BioStealth™ technology in systemic vascular treatments and even bio-artificial organs. For professionals looking to make a tangible impact on global health, Global Vascular offers a rare opportunity to be part of a Japanese startup that is truly destined for the global stage.